Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klastersky, J
Right arrow Articles by Thys, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Klastersky, J
Right arrow Articles by Thys, J.

Chest, Vol 75, 586-591, Copyright © 1979 by American College of Chest Physicians

ARTICLES

Endotracheally administered antibiotics for gram-negative bronchopneumonia

J Klastersky, F Carpentier-Meunier, L Kahan-Coppens and JP Thys

Sisomicin or a placebo was administered endotracheally to two groups of 18 and 20 unconscious patients, respectively, who had tracheostomies or endotracheal tubes in place and developed a severe gram-negative broncho-pneumonia. In addition, the patients received systemically a combination of sisomicin and carbenicillin. A favorable clinical response was obtained in 14 (77 percent) of the 18 patients who were treated with sisomicin and in nine (45 percent) of the 20 patients who received the placebo (P less than 0.05). Endotracheal therapy with sisomicin was well tolerated and resulted in high levels of sisomicin and in elevated bactericidal activity within the bronchial secretions. Endotracheally administered amino-glycosides might be an important adjunct to systemically administered antibiotics in the management of severe gram-negative bronchopneumonia.


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. R. Badia, D. Soy, M. Adrover, M. Ferrer, M. Sarasa, A. Alarcon, C. Codina, and A. Torres
Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients
J. Antimicrob. Chemother., August 1, 2004; 54(2): 508 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. Goldstein, F. Wallet, A. Nicolas-Robin, F. Ferrari, C.-H. Marquette, and J.-J. Rouby
Lung Deposition and Efficiency of Nebulized Amikacin during Escherichia coli Pneumonia in Ventilated Piglets
Am. J. Respir. Crit. Care Med., November 15, 2002; 166(10): 1375 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Chastre and J.-Y. Fagon
Ventilator-associated Pneumonia
Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 867 - 903.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the American College of Chest Physicians.